Menu
Create an Account
Log in
Home
Activities
Courses and Conferences
HIV In-Person and Virtual Courses
Earn CME From On-Demand Webcasts
The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Conference on Retroviruses and Opportunistic Infections
About IAS–USA Courses
Webinars
Upcoming Webinars
2022 On-Demand Webinars
Earn CME From On-Demand Webinars
About Webinars
COVID-19 Dialogue Series
Upcoming Dialogues
On-Demand Dialogues
Topics in Antiviral Medicine
Current Issues
Previous Issues
TAM
Policies and Practices
Resources
Guidelines
HIV Drug Resistance Mutations
Podcasts
On-Demand Webcasts
Slides
Research Collaboration
Useful Resources for COVID-19 Information and Guidance
Practice Question of the Week
Fellow/Student Resources
Other Resources
About
Mission
IAS–USA Scientific Leadership Board
IAS–USA Governance
Core Faculty
Staff
CME
Funding Information
Careers
Donate
Website Policies
FAQs
Contact
Professors
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Page 1 of 26
1
2
3
4
5
...
10
20
...
»
Last »
Home
Activities
Courses and Conferences
HIV In-Person and Virtual Courses
Earn CME From On-Demand Webcasts
The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Conference on Retroviruses and Opportunistic Infections
About IAS–USA Courses
Webinars
Upcoming Webinars
2022 On-Demand Webinars
Earn CME From On-Demand Webinars
About Webinars
COVID-19 Dialogue Series
Upcoming Dialogues
On-Demand Dialogues
Topics in Antiviral Medicine
Current Issues
Previous Issues
TAM
Policies and Practices
Resources
Guidelines
HIV Drug Resistance Mutations
Podcasts
On-Demand Webcasts
Slides
Research Collaboration
Useful Resources for COVID-19 Information and Guidance
Practice Question of the Week
Fellow/Student Resources
Other Resources
About
Mission
IAS–USA Scientific Leadership Board
IAS–USA Governance
Core Faculty
Staff
CME
Funding Information
Careers
Donate
Website Policies
FAQs
Contact
Practice Question of the Week
June 27, 2022: Pharmacokinetics (PK) and PK-Pharmacodynamics (PD) of Nirmatrelvir/Ritonavir
Which of the following statements regarding the pharmacokinetic (PK) and PK-pharmacodynamics (PD) of nirmatrelvir/ritonavir is CORRECT?
A. Nirmatrelvir is highly protein bound
B. The protein-adjusted 90% effective concentration (EC90) for nirmatrelvir is 292 ng/mL
C. Race, weight, and renal function influence nirmatrelvir PK
D. In the EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) and EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trials in persons with COVID-19, those with a nirmatrelvir trough above 1000 ng/mL had faster time to symptom resolution
Watch Webinar
View Related Resources
Leave Feedback
Subscribe
CLOSE